Medicinal products for human use
Good Distribution Practice
The wholesale distribution of medicinal products is an important activity in the integrated supply chain management. . The quality and the integrity of medicinal products can be affected by a lack of adequate control. To this end, the Commission has published guidelines on good distribution practice of medicinal products for human use in form of a Commission guideline 94/C 63/03
The present guidelines are based on Articles 84 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use ("Directive 2001/83/EC').
A new version of the Guidelines on good distribution practice (GDP) of medicinal products was published today
The revised guidelines (OJ C 343/1, 23.11.2013) correct factual mistakes in subchapters 5.5 and 6.3, give more explanations on the rationale for the revision and provide a formal date of coming into operation. These guidelines, which replace the guidelines on GDP published in March 2013, are applicable as of 24 November 2013.
Responses to the public consultation on draft guidelines on the principles of good distribution practices for active substances for medicinal products for human use.
- AESGP-Association Européenne des Spécialités Pharmaceutiques Grand Public
- APIC-Active Pharmaceutical Ingredients Committee
- DEUTSCHE POST DHL
- EFPIA-European Federation of Pharmaceutical Industries
- EISAI Manufacturing Limited
- FECC-European Association of Chemical Distributors
- FRESENIUS-Kabi Deutschland GMBH
- GIRP - European Association of Pharmaceutical Full-line Wholesalers
- Glenmark Pharmaceuticals
- ISPE - International Society for Pharmaceutical Engineering
- LEEM - Les entreprises du médicaments
- PDA - Parenteral Drug Association
- PHARMIG - Association of the Austrian pharmaceutical industries
- POLISH HERBAL Committee
- QUEMACO - Chemical Marketing Company
- RANBAXY Lab
- SCIENCE PHARMA
- SGAE - Secrétariat Général des Affaires Etrangères France
- The Finnish Pharmacists’ Society
- VDC - Drug and Chemical Association
- White Wave - Pharmaceutical Consultancy Company
- Yusen Logistics (UK) Ltd
Gedeon Richter Plc., Merck KGaA, Teva Pharmaceutical Industries Ltd. and UCB Pharma SA requested that their response not be published.
Revised rules on the distribution of medicinal products in the EU
It is of key importance that the quality and the integrity of the medicinal products are maintained during the entire supply chain from the manufacturer to the patient.
Today’s distribution network for medicinal products is increasingly complex and involves many players. The revised guidelines, published today, lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified medicines from entering the legal supply chain.
The revised guidelines introduce the following changes:
- the maintenance of a quality system setting out responsibilities, processes and risk management principles in relation to wholesale activities;
- suitable documentation which prevents errors from spoken communication;
- sufficient competent personnel to carry out all the tasks for which the wholesale distributor is responsible;
- adequate premises, installations and equipment so as to ensure proper storage and distribution of medicinal products;
- appropriate management of complaints, returns, suspected falsified medicinal products and recalls;
- outsourced activities correctly defined to avoid misunderstandings;
- rules for transport in particular to protect medicinal products against breakage, adulteration and theft, and to ensure that temperature conditions are maintained within acceptable limits during transport;
- Specific rules for brokers (person involved in activities in relation to the sale or purchase of medicinal products).
Wholesale distribution of medicinal products is "all activities consisting of procuring, holding, supplying or exporting medicinal products, apart from supplying medicinal products to the public. Such activities are carried out with manufacturers or their depositories, importers, other wholesale distributors or with pharmacists and persons authorized or entitled to supply medicinal products to the public in the Member State concerned".
The revised guidelines will enter into force in six months from the date of publication, on 8 September 2013.
Important: Please note that the obligation to record the batch number will only enter into force 3 years after the delegated act on the safety features is adopted by the Commission (adoption foreseen in 2014).
Responses to the public consultation on the "Revised Commission guidelines on Good Distribution Practice of Medicinal Products for human use"
The responses are published here.
Public consultation of the revised Commission guidelines on Good Distribution Practice of Medicinal Products for Human Use
Today, DG SANCO launches a public consultation on the revised guidelines for good distribution practices. The content of the Guidelines on Good Distribution Practice published in 1994 is no longer adequate. It needs to be reviewed to take into account advancements of practices for an appropriate storage and distribution of medicinal products in the European Union. Moreover, it needs to consider the new requirements for wholesale distributors and brokers established by the new Directive 2011/62/EU of the European Parliament and of the Council amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products.
Comments and suggestions are invited by 31 December 2011 and should be sent by email to: mailto:SANCOemail@example.com ADM-GMDP@ema.europa.eu